rct
    2007
    High Quality

    Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial

    Stremmel W, Ehehalt R, Autschbach F, Karner M

    Published in Annals of Internal Medicine

    Methodology

    Randomized double-blind placebo-controlled trial of delayed-release phosphatidylcholine in steroid-refractory chronic active ulcerative colitis

    Key Findings

    Complete steroid withdrawal was achieved in 80% of phosphatidylcholine patients versus 10% of placebo patients

    Conclusions

    Delayed-release phosphatidylcholine facilitates steroid withdrawal in refractory ulcerative colitis

    Limitations

    Single-centre trial with a small sample and one investigator group

    Supplements Studied

    Complete steroid withdrawal was achieved in 80% of phosphatidylcholine patients versus 10% of placebo patients

    Related Health Concerns

    Inflammatory Bowel Disease
    Ulcerative Colitis

    Study Details

    Year:2007
    Sample Size:60
    Duration:12 weeks
    Quality Score:7/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.